ONCOLYTICS BIOTECH INC 8-K

What Happened
On March 20, 2026, Oncolytics Biotech Inc. (ONCY) filed an 8-K reporting the consummation of its continuance from Alberta to British Columbia. As part of the continuance the company adopted a continuation application that included a Notice of Articles and new Articles of Oncolytics Biotech Inc., and the rights of holders of the company’s common shares are now governed by the Articles and the British Columbia Business Corporations Act (BCBCA). The Circular/Prospectus forming part of the company’s Form F-4 (declared effective December 9, 2025) describes these documents and includes an “Annex J—Material Differences between Alberta Corporate Law and British Columbia Corporate Law.”

Key Details

• 8-K filed March 20, 2026 reporting Items 3.03 (material modification of security-holder rights) and 5.03 (amendments to articles).
• Company completed a formal continuance from Alberta to British Columbia and adopted Notice of Articles and Articles governing shareholder rights.
• The governance regime for common shareholders shifted from rules under the Alberta Business Corporations Act (ABCA) to the BCBCA; the Circular/Prospectus (Form F-4, File No. 333-290954) explains material differences.
• Exhibits filed with the 8-K: Certificate of Continuation issued by the British Columbia Registrar, the Notice of Articles, and the Articles (plus the Inline XBRL cover page).

Why It Matters
This filing documents a legal change that modifies the formal rights and governance framework for Oncolytics’ shareholders because the company moved its jurisdiction from Alberta to British Columbia. That change can affect shareholder protections, corporate governance rules, and certain statutory rights; the Circular/Prospectus and the newly filed Articles provide the detailed differences. Investors should review the Form F-4 Circular/Prospectus (and the Exhibits filed with this 8-K) to understand any specific impacts on voting, remedies, or other shareholder rights.